Karo Bio forced to abandon Phase III-stage eprotirome
This article was originally published in Scrip
Executive Summary
Karo Bio's future looks uncertain following news that it is dropping its Phase III-stage drug candidate eprotirome after a preclinical study demonstrated "unwanted effects following long-term exposure". As a result, the planned spin-off of the company's preclinical operations into a separate entity will not proceed.
You may also be interested in...
Madrigal's Early Phase IIb NASH Data Show Clinically Meaningful Fat Reduction
Analysts and investors also voice excitement about the THR-beta agonist's lipid-lowering effects to date. For Madrigal, the key will be replicating its 12-week data at 36 weeks, when the trial ends.
Madrigal Believes It Holds The Key To NASH: Clearing The Fat
Emerging Company Profile: With its first-in-class selective THR beta agonist, Madrigal thinks it may have a candidate, now in Phase II, that will offer reversal of liver damage in NASH patients with an excellent safety profile. It hopes to begin Phase III studies with MGL-3196 before the end of 2018.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.